Value of PLR in efficacy and prognosis of targeted therapy for NSCLC with EGFR mutation
10.3969/j.issn.1006-5725.2019.04.007
- VernacularTitle:血小板与淋巴细胞比值在表皮生长因子受体突变型非小细胞肺癌靶向治疗疗效与预后评价中的价值
- Author:
Guanming JIANG
1
;
Kejun LIU
;
Qinquan TAN
;
Yihong ZENG
;
Haiji YUAN
;
Shunhuan LIN
Author Information
1. 东莞市人民医院肿瘤内科
- Keywords:
non-small cell lung cancer;
epidermal growth factor receptor;
platelet-lymphocyte ratio;
targeted therapy;
prognosis
- From:
The Journal of Practical Medicine
2019;35(4):533-536
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of PLR in peripheral blood in the efficacy and prognosis of targeted therapy for NSCLC with EGFR-mutated. Methods Ninety patients with EGFR-mutant of NSCLC were selected, and the PLR was calculated before targeted therapy. The PLR median was used as a cut-off point for grouping, and they were assigned to group A (low PLR group) and group B (high PLR group). All patients were treated with EGFR-TKIs. Relationship between PLR and clinicopathological features was analyzed. Objective efficacy, ORR, DCR, PFS and OS between the two groups were compared. Results Before EGFR-TKIs therapy, median PLR was 139, and there were 44 patients in group A, and 46 in group B. There were statistical differences regarding smoking, tumor location, histological differentiation, T staging, and clinical staging between group A and B (P <0.05). The rates of PR, ORR and DCR in group A were higher than those in group B, and the PD rate was lower than that in group B (P < 0.05). Log-rank test showed that median OS and median PFS in group A were longer than those in group B (P= 0.001). Conclusions PLR in peripheral blood has certain reference value for therapeutic effect and prognosis evaluation on NSCLC with EGFR-mutation. Low PLR of NSCLC patients with EGFR-mutation has higher efficacy and longer survival time after targeted therapy, and it is an independent and prognostic factor.
